- Conditions
- Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
- Interventions
- Balfaxar, Kcentra
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,574 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced May 22, 2026, 5:44 AM EDT